Efficacy & Tolerance of Cosmetic Product RV5098A on Face Pigmentation Maintenance in Adult Vitiligo Patients.

Launched by PIERRE FABRE DERMO COSMETIQUE · May 31, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a topical product called RV5098A to see if it can help maintain the skin color in adults with facial vitiligo after they have received treatment to restore pigmentation. Vitiligo is a condition where the skin loses its color due to a problem with the cells that create pigment. The goal of this study is to find out if RV5098A can prevent the color from fading again after successful treatment, as about 40% of people experience a return of their vitiligo within a year after treatment stops.

To be eligible for this trial, participants need to be between 18 and 75 years old and have facial vitiligo that has shown a good response to previous treatments. However, people with active vitiligo or other skin conditions, as well as those taking certain medications, won't be able to join. Participants in the study can expect to apply the RV5098A product as directed and will be monitored to see how well it works in keeping their skin color stable. This trial is currently recruiting participants, and it could be a valuable opportunity for those looking for better ways to manage their vitiligo.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Criteria related to the population:
• • - Subject aged between 18 and 75 years included.
• Criteria related to the disease:
• • Subject with facial vitiligo, regardless of its duration.
• • having a sufficient repigmentation rate of the vitiligo after repigmenting treatment
• Criteria related to treatments and/or products:
• • - Subject responder to a repigmenting treatment
• Non-inclusion Criteria:
• Criteria related to the diseases / skin condition:
• • Subject with active vitiligo.
• • Subject with spontaneous repigmentation without treatment.
• • Subject having other dermatological condition, an acute, chronic, or progressive disease or history of disease liable to interfere with the study assessments or considered by the Investigator hazardous for the subject or incompatible with the study requirements.
• Criteria related to treatments and/or products:
• • Systemic immunomodulatory treatment taken for another pathology, before inclusion, on-going or planned to be established during the study.
• • Any topical immunomodulatory treatment applied on the face for another pathology, on-going or planned to be established during the study.
• • Any other topical or systemic treatment established or modified during the previous weeks or planned to be established or modified during the study, liable to interfere with the evaluation of the efficacy according to the investigator's assessment.
• • Any dietary supplement for vitiligo within 4 weeks before the inclusion visit or planned to be established during the study.

Trial Officials